{"id":4588,"date":"2020-02-11T05:00:48","date_gmt":"2020-02-11T05:00:48","guid":{"rendered":"http:\/\/blogs.sld.cu\/oserranob\/?p=4588"},"modified":"2020-02-13T04:21:06","modified_gmt":"2020-02-13T04:21:06","slug":"modifican-linfocitos-t-para-luchar-contra-cancer-refractario","status":"publish","type":"post","link":"https:\/\/blogs.sld.cu\/oserranob\/2020\/02\/11\/modifican-linfocitos-t-para-luchar-contra-cancer-refractario\/","title":{"rendered":"Modifican linfocitos T para luchar contra c\u00e1ncer refractario"},"content":{"rendered":"<p style=\"text-align: justify\"><a href=\"https:\/\/blogs.sld.cu\/oserranob\/files\/2020\/02\/2020-02-12-CRISPR-T.jpg\"><img loading=\"lazy\" class=\"alignleft wp-image-4598 size-full\" style=\"border-width: 1px;margin: 5px\" title=\"(c) Stadtmauer EA, et al. Science 2020\" src=\"https:\/\/blogs.sld.cu\/oserranob\/files\/2020\/02\/2020-02-12-CRISPR-T.jpg\" alt=\"2020 02 12 CRISPR T\" width=\"85\" height=\"112\" \/><\/a>Con el uso de CRISPR-Cas9, la edici\u00f3n m\u00faltiple del genoma de linfocitos T produjo c\u00e9lulas con una mayor capacidad antitumoral, que se mantuvieron viables al menos por 9 meses. La nueva evidencia de las posibilidades de esta opci\u00f3n terap\u00e9utica es descrita en Stadtmauer EA, Fraietta JA, Davis MM, Cohen AD, Weber KL, Lancaster E, <em>et al<\/em>. <a title=\"Texto completo en ingl\u00e9s\" href=\"https:\/\/science.sciencemag.org\/content\/early\/2020\/02\/05\/science.aba7365\" target=\"_blank\">CRISPR-engineered T cells in patients with refractory cancer<\/a>. Science 2020:eaba7365.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Con el uso de CRISPR-Cas9, la edici\u00f3n m\u00faltiple del genoma de linfocitos T produjo c\u00e9lulas con una mayor capacidad antitumoral, que se mantuvieron viables al menos por 9 meses. La nueva evidencia de las posibilidades de esta opci\u00f3n terap\u00e9utica es descrita en Stadtmauer EA, Fraietta JA, Davis MM, Cohen AD, Weber KL, Lancaster E, et [&hellip;]<\/p>\n","protected":false},"author":125,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":[],"categories":[11,23,39],"tags":[],"_links":{"self":[{"href":"https:\/\/blogs.sld.cu\/oserranob\/wp-json\/wp\/v2\/posts\/4588"}],"collection":[{"href":"https:\/\/blogs.sld.cu\/oserranob\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.sld.cu\/oserranob\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.sld.cu\/oserranob\/wp-json\/wp\/v2\/users\/125"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.sld.cu\/oserranob\/wp-json\/wp\/v2\/comments?post=4588"}],"version-history":[{"count":3,"href":"https:\/\/blogs.sld.cu\/oserranob\/wp-json\/wp\/v2\/posts\/4588\/revisions"}],"predecessor-version":[{"id":4599,"href":"https:\/\/blogs.sld.cu\/oserranob\/wp-json\/wp\/v2\/posts\/4588\/revisions\/4599"}],"wp:attachment":[{"href":"https:\/\/blogs.sld.cu\/oserranob\/wp-json\/wp\/v2\/media?parent=4588"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.sld.cu\/oserranob\/wp-json\/wp\/v2\/categories?post=4588"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.sld.cu\/oserranob\/wp-json\/wp\/v2\/tags?post=4588"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}